drugset / Trial / NCT00663026
Study Evaluating Bapineuzumab In Alzheimer Disease Subjects
RandomizedParallel-groupTriple-blindTreatment
Summary
The study will evaluate the safety and effectiveness of bapineuzumab for the treatment of mild to moderate Alzheimer disease. Subjects will be in the study for six months and will receive subcutaneous injections once per week.
Timeline
- Start
- 2008-11
- Primary completion
- 2010-10
- Completion
- 2010-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | bapineuzumab | Monoclonal antibody | 5 mg | Subcutaneous |
| Subject | bapineuzumab | Monoclonal antibody | 10 mg | Subcutaneous |